Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT) Strand, V., Rendas-Baum, R., Joseph, G. J., Chen, C., van Hoogstraten, H., Huizinga, T. J., Genovese, M. C. WILEY-BLACKWELL. 2015
View details for Web of Science ID 000370860203717